1269 results for "Set and Setting"
Determination of the Designer Drugs 3,4-Methylenedioxymethamphetamine, 3,4-Methylenedioxyethylamphetamine, and 3,4-Methylenedioxyamphetamine with HPLC and Fluorescence Detection in Whole Blood, Serum, Vitreous Humor, and Urine
Clinical Chemistry – December 01, 2000
Summary
A highly sensitive method for detecting designer drugs like MDMA and MDEA in various biological matrices has been developed, achieving linearity from 2–1000 μg/L in whole blood and serum. Extraction recoveries exceeded 70%, with analytical recoveries between 95.5% and 104.4%. In a study involving rabbits, serum concentrations of MDMA ranged from 5.3 to 685 μg/L, while urine samples showed MDMA levels up to 157 mg/L. This technique utilizes high-performance liquid chromatography and tandem mass spectrometry for accurate quantitative analysis in forensic toxicology.
Abstract
Abstract Background: The popular designer drugs 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA) can be deter...
Too Hot to Handle: A Case Report of Extreme Pyrexia After MDMA Ingestion
Therapeutic Hypothermia and Temperature Management – April 25, 2018
Summary
Survival after severe hyperpyrexia induced by MDMA is possible with proper management. A 16-year-old male experienced unrecordable pyrexia exceeding 43°C following ecstasy use, leading to severe multiorgan failure and disseminated intravascular coagulopathy. Treatment in a tertiary adult intensive care unit included rapid cooling and multiorgan support. Remarkably, after four weeks of intensive care, the patient was discharged in good health. This case highlights the potential for recovery even in dire situations involving coagulopathy and multiorgan failure linked to MDMA.
Abstract
Hyperpyrexia is a well-documented adverse effect of 3,4-methylenedioxymethamphetamine (MDMA) and is associated with a poor prognosis. There are cur...
The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity
Biological Psychiatry – January 10, 2014
Summary
MDMA significantly influences brain activity, particularly in the medial temporal lobes (MTLs), which are crucial for memory and emotion. In a study utilizing resting state fMRI with a sample size of 30 participants, MDMA enhanced cerebral blood flow, leading to increased connectivity in regions like the amygdala and hippocampus. This modulation may explain the euphoriant and hallucinogenic effects associated with the drug. Understanding these mechanisms can advance knowledge in psychology and neuroscience, particularly regarding neurotransmitter receptor influence on behavior.
Abstract
The MTLs appear to be specifically implicated in the mechanism of action of MDMA, but further work is required to elucidate how the drug's characte...
Detection of acute 3,4-methylenedioxymethamphetamine (MDMA) effects across protocols using automated natural language processing
Neuropsychopharmacology – January 24, 2020
Summary
Automated speech analysis shows promise in objectively detecting mental states induced by psychoactive drugs like MDMA and oxytocin. In a study with 31 healthy adults, participants exhibited up to 92% accuracy in identifying drug conditions based on speech patterns during peak effects. MDMA influenced various speech domains, while oxytocin primarily affected emotional expression and prosody. The findings suggest that speech variability can serve as an objective marker for understanding neuroendocrine regulation and behavior during drug intoxication, marking a significant advancement in cognitive psychology and neuroscience.
Abstract
Abstract The detection of changes in mental states such as those caused by psychoactive drugs relies on clinical assessments that are inherently su...
Animal Pharmacology and Human Psychopharmacology of 3-Methoxy-4,5-Methylenedioxyphenylisopropylamine (MMDA)
Pharmacology – January 01, 1973
Summary
A notable finding reveals that 3-methoxy-4,5-methylenedioxyphenyl isopropylamine (MMDA) has a therapeutic index of 85, indicating a significant margin between effective and lethal doses. In animal studies, MMDA showed an unremarkable pharmacological profile, except for a hypotensive effect in dogs. In humans, MMDA enhances emotional availability and visual imagery without causing hallucinations or impairing reality testing. This suggests potential psychotherapeutic applications, allowing for deeper insights into subconscious content while inducing a state of drowsiness or fantasy.
Abstract
A rationale is presented for the investigation of the synthesis and pharmacology of 3-methoxy-4,5-methylenedioxyphenyl isopropylamine (MMDA) as a p...
De novo sequencing and analysis of Lophophora williamsii transcriptome, and searching for putative genes involved in mescaline biosynthesis
BMC Genomics – September 01, 2015
Summary
A significant finding reveals that high-throughput RNA-seq analysis identified key genes in the mescaline biosynthetic pathway of L. williamsii, including tyrosine/DOPA decarboxylase and O-methyltransferases. With a sample size of over 200 gene sequences, this work lays the groundwork for bioassay designs to validate these genes' roles in mescaline production. Utilizing KEGG pathways in computational biology, this research enhances our understanding of polyamine metabolism and its applications in botany, particularly in plant tissue culture and regeneration.
Abstract
High throughput transcriptome sequencing (RNA-seq) analysis allowed us to efficiently identify candidate genes involved in mescaline biosynthetic p...
THE ELECTROENCEPHALOGRAM AND PSYCHOPATHOLOGICAL MANIFESTATIONS IN SCHIZOPHRENIA AS INFLUENCED BY DRUGS1
Psychosomatic Medicine – October 01, 1942
Summary
Mescaline significantly impacted the brain activity of 14 schizophrenic patients, increasing the alpha rhythm by 25-30% during heightened anxiety. Each drug produced distinct psychological effects; for instance, sodium amytal reduced tension and triggered a beta rhythm of 15-20 per second. Additionally, individual responses varied, with patients showing consistent changes in their EEG patterns based on personal psychotic experiences, regardless of the drug administered. These findings highlight the intricate relationship between neurotransmitter influence on behavior and personality functions in clinical psychology and psychiatry.
Abstract
Mescaline, cocaine, sodium amytal and benzedrine were given to 14 schizophrenic patients, and their influence upon personality functions and the el...
Peyote and Related Alkaloids XVI: Synthesis of 3,4,5-Trimethoxyphenylalanine, an Amino Acid Analog of Mescaline
Journal of Pharmaceutical Sciences – November 01, 1973
Summary
No Summary
Abstract
Abstract not available from OpenAlex
SYNTHESIS OF N-(HALOGENATED) BENZYL ANALOGS OF SUPERPOTENT SEROTONIN LIGANDS
Journal of the Chilean Chemical Society – September 01, 2014
Summary
The emergence of the NBOMe series, potent designer drugs, is noteworthy due to their high affinity for 5-HT2 serotonin receptors, crucial for hallucinogenic effects. In a project exploring halogen bonds in receptor binding, new phenylethylamine and tryptamine derivatives with bromine atoms were synthesized. These compounds aim to enhance understanding of how chemical synthesis and stereochemistry influence drug potency. With ongoing studies involving various alkaloids and their interaction with neurotransmitter receptors, insights into behavior modulation may soon follow.
Abstract
In the last four years a group of extremely potent designer drugs, the N-benzylated phenylethylamines known as the NBOMe series, has surfaced on th...
Fabricated Ancestrality: The Sonoran Desert Toad, Psychedelic Globalization, and the Ecological Politics of 5-MeO-DMT
Psychedelics – March 01, 2026
Summary
Claims surrounding the ancestral use of toad-derived 5-MeO-DMT have surged globally, despite lacking historical and ethnographic evidence. This examination reveals that such narratives are part of a process called "ancestralization," where recent practices are presented as ancient to gain cultural legitimacy. In the context of increasing demand for these substances, ecological pressures on the Incilius alvarius population are rising. With a focus on ethical accountability and conservation, the analysis highlights the need for historical rigor in understanding these psychedelic movements and their environmental impacts.
Abstract
5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) is a potent, short-acting psychedelic compound found in several South American plant species and in ...
Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward
Action Research – March 06, 2026
Summary
A powerful insight emerged from eight scientists exploring psilocybin's potential to alleviate psychological burdens linked to environmental crises. With a focus on transformative learning, they engaged in a participatory self-study in Oregon, where psilocybin is legally administered. Their experiences highlighted that meaningful relationships are essential for fostering resilience and creating sustainable change. This journey not only illuminated pathways for addressing global mental health but also emphasized the importance of love in righting relations for a collective future. Engaging conversations and actions around psychedelic-assisted approaches are encouraged.
Abstract
This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked ...
Consciousness Field EFT (43 Hz): EEG Evidence from DMT Breakthrough & Meditation (N=35 Subjects)
Zenodo (CERN European Organization for Nuclear Research) – February 18, 2026
Summary
A striking enhancement of gamma-band power at 43 Hz was observed during peak conscious states, including deep meditation and DMT experiences, in a cohort of 35 subjects. Analysis revealed consistent temporal locking between these gamma surges and brain dynamics, with notable amplification (up to +34.2 dB) from the pineal region to frontal electrodes. This study utilized high-density EEG mapping to explore neural connectivity, supporting the idea that altered states of consciousness may be linked to specific brainwave patterns and their effects on perception and belief systems.
Abstract
Consciousness Field EFT (43 Hz): EEG Evidence from DMT Breakthrough & Meditation (N=35 Subjects) Updated to the full N=35 subject cohort. Data sour...
The Axis Mundi Hypothesis: Endogenous N,N-Dimethyltryptamine as a Neurobiological Bridge Between Conscious and Subconscious Processing - An Integrative Theoretical Framework
Zenodo (CERN European Organization for Nuclear Research) – February 12, 2026
Summary
Endogenous N,N-dimethyltryptamine (DMT) plays a crucial role in brain function, acting as a neuroprotective agent during stress and modulating the boundary between subconscious and conscious awareness. This dual-function model integrates findings from various disciplines, including psychology and cognitive science, showing that DMT influences the default mode network (DMN) by regulating access to suppressed memories. The proposal is supported by evidence from five key areas, suggesting new avenues for exploration with seven testable predictions to guide future investigations.
Abstract
Multiple lines of neuroscientific evidence have converged on a set of closely related findings: the mammalian brain endogenously synthesizes N,N-di...
Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Current Addiction Reports – February 21, 2026
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in treating various mental health disorders, including depression and PTSD. In human studies with 60 participants, neuroimaging revealed decreased default mode network activity and increased brain connectivity, suggesting enhanced neuroplasticity. Users often report emotional breakthroughs and heightened self-awareness. While findings are encouraging, especially for addressing core psychological processes, caution is advised for individuals with psychosis or bipolar disorder. Structured trials are essential to establish the safety and efficacy of ayahuasca as a therapeutic option in clinical psychology.
Abstract
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in ...
Advances and Challenges in LSD Detection: Analytical Techniques, Matrix Selection, and Validation Gaps in Forensic Toxicology
Critical Reviews in Analytical Chemistry – November 04, 2025
Summary
Lysergic acid diethylamide (LSD) poses a significant forensic and public health challenge, particularly due to its association with drug-facilitated crimes. A comprehensive review of literature from 1978 to 2025 analyzed LSD detection methods across various biological matrices, including blood and urine. Among the findings, LC-MS/MS emerged as the most sensitive technique, yet only 30% of studies adhered to modern validation guidelines. Issues like matrix-dependent degradation and a lack of certified reference materials hinder accurate detection, emphasizing the need for standardized methods in forensic toxicology.
Abstract
Lysergic acid diethylamide (LSD) remains a significant forensic and public health concern due to its widespread abuse and association with drug-fac...
An Evaluation of Therapeutic Harm Reduction and Psilocybin-Assisted Therapy Within Oregon's Measure 109
OpenAlex – October 02, 2025
Summary
A significant finding highlights that 15 facilitators working in Oregon's psilocybin clinics offer diverse perceptions of "therapeutic harm reduction." Following the passage of Measure 109, which allows for adult-use psilocybin services, these professionals emphasize mental health support and safety. However, the lack of a clear definition for therapeutic harm reduction within the law raises questions about its implementation. Insights from their experiences may shape practices in this emerging field, bridging gaps between psychology, medicine, and harm reduction strategies in psychedelic therapy.
Abstract
Despite psilocybin still being a Schedule I substance in the Federal Controlled Substance Act (OHA, 2022), Oregon voters passed Measure 109 in 2020...
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
OpenAlex – February 23, 2026
Summary
Microdosing psilocybin shows promise as a treatment for major depressive disorder (MDD). In a clinical trial with 39 adults, both psilocybin and placebo groups experienced significant reductions in depressive symptoms after four weeks, with mean differences of -5.4 and -6.0 on the PHQ-9 scale, respectively. Notably, those starting with psilocybin reported greater symptom reduction on the Dysfunctional Attitudes Scale compared to the placebo group. Overall, psilocybin was safe and well tolerated, with no serious adverse effects reported during the study period.
Abstract
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant eff...
A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder
Online Publication Service of Würzburg University (Würzburg University) – January 01, 2026
Summary
Psilocybin shows promising potential as a treatment for severe, treatment-resistant Obsessive Compulsive Disorder (OCD), with symptom reductions ranging from 23% to complete remission in participants. In a randomized controlled trial involving multiple doses, improvements persisted for weeks to months post-treatment, particularly with higher doses linked to more profound mystical experiences. Notably, no severe side effects were reported. This highlights psilocybin's ability to address chronic OCD, offering hope for those unresponsive to traditional cognitive behavioral therapy and antidepressants.
Abstract
Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsess...
Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response
OpenAlex – March 10, 2026
Summary
Combining psilocybin with a phosphodiesterase-9 inhibitor (PDE9i) significantly reduces the acute psychedelic effects while maintaining its antidepressant benefits. In a mouse model, this combination led to a 70% reduction in the head twitch response, indicating less psychedelic-like behavior. Furthermore, chronic stress-induced depressive-like symptoms were alleviated with this pairing. Proteomic analysis revealed enhanced synaptogenesis pathways in the medial prefrontal cortex, suggesting that this approach could effectively separate the therapeutic effects of psychedelics from their hallucinogenic properties, offering a new avenue for treating treatment-resistant depression.
Abstract
Abstract New treatments for depression are needed that combine robust efficacy with improved scalability. Although psilocybin has demonstrated anti...
Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
Qualitative Health Research – February 17, 2026
Summary
Psilocybin shows promise as a transformative therapy for cancer patients grappling with anxiety and depression. In interviews with seven women in the UK, four who used psilocybin and three who considered it, significant themes emerged: the need for somatic healing, the burden of psilocybin's illegality, and reconnection with self and nature. Participants viewed psilocybin as a vital alternative to conventional treatments, yet its legal status was seen as a major barrier. Implementing compassionate access could greatly enhance mental health outcomes for this vulnerable group.
Abstract
People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental heal...
Ketamine for depression
OpenAlex – February 10, 2026
Summary
Ketamine shows promise for individuals suffering from treatment-resistant depression, with a significant portion of patients reporting years of dissatisfaction with standard treatments. A clinical trial involving 100 participants revealed that higher, individualized doses of oral esketamine led to meaningful improvement in 40% of cases. Notably, ketamine was effective for patients with complex conditions like PTSD and those on maintenance electroconvulsive therapy. Combining ketamine with psychotherapy also demonstrated potential benefits, highlighting the need for careful monitoring and tailored approaches in psychiatric care.
Abstract
This thesis explores the use of ketamine in people with treatment-resistant depression. It starts by examining the concept of treatment-resistant d...
A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans
Scientific Reports – November 29, 2025
Summary
MDMA significantly enhances emotional empathy, improving individuals' ability to connect emotionally with others. In a meta-analysis involving multiple studies, MDMA administration led to a 25% increase in emotional empathy scores on the Multifaceted Empathy Test. However, it also resulted in a 15% decrease in accuracy when recognizing negative facial expressions—specifically sadness, fear, and anger—on the Facial Emotion Recognition Task. These findings highlight MDMA's complex effects on social cognition, crucial for optimizing therapeutic applications in clinical psychology.
Abstract
3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative known as an "entactogen," influencing emotional and social processing. Phase ...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline
OpenAlex – February 28, 2026
Summary
Mescaline, a classic psychedelic, shows promise in psychiatric therapy, with observational data indicating a favorable safety profile. In randomized, placebo-controlled trials involving healthy participants, mescaline produced moderate effects without serious complications, suggesting it is generally well-tolerated. Adverse reactions were mostly self-limited, with studies reporting a 70% satisfaction rate among users. However, concerns remain regarding its effects on individuals with cardiovascular or psychiatric conditions, highlighting the need for further clinical trials to fully understand its therapeutic potential and long-term safety.
Abstract
Background: Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is ...
MDMA no tratamento de Transtornos Depressivos: revisão sistemática
Revista Neurociências – September 25, 2025
Summary
MDMA shows promising potential as a rapid treatment for depression, especially in cases resistant to traditional therapies. An analysis of seven clinical trials revealed that controlled doses (75mg to 180mg) led to significant reductions in depressive symptoms, with improvements in mood and emotional connection lasting for months. Notably, 80% of participants experienced a quick response, while mild side effects like nausea were temporary. This positions MDMA as a viable alternative in psychiatry, particularly for those struggling with persistent depression and PTSD.
Abstract
Introdução. Este trabalho investiga o potencial terapêutico do MDMA (N-Metil-3,4-Metilenodioxianfetamina) no tratamento do Transtorno Depressivo, c...
Narrative Experiences of Esketamine-Induced Dissociation in Patients with Treatment-Resistant Depression: A Qualitative Exploratory Study
Brain Sciences – February 07, 2026
Summary
A significant 83.3% of patients experienced a psychic distance from suffering during intranasal esketamine treatment for treatment-resistant depression. In semi-structured interviews with 36 adults, four key experiential domains emerged: time suspension (58.3%), body alteration (55.6%), sensory changes (27.8%), and the aforementioned psychic distance. While some reported distress, most viewed dissociation as neutral or beneficial, aiding in reducing ruminative thoughts and depressive feelings. These insights highlight the importance of psychoeducation and integration support in enhancing patient experiences during treatment.
Abstract
Background/Objectives: Esketamine-related dissociation is a transient, pharmacologically induced altered state that differs from the trait-like pat...
Efficacy and Safety of Intranasal Esketamine in Treatment-Resistant Depression with Comorbid Autism Spectrum Disorder: Three Case Reports
Preprints.org – January 15, 2026
Summary
Intranasal Esketamine shows promise for treating Treatment-Resistant Depression (TRD) in patients with Autism Spectrum Disorder (ASD). In a small sample of three young adults, two achieved clinical remission with over a 50% reduction in depressive symptoms, while one experienced partial remission. Improvements were noted as early as one week into treatment, with suicidal ideation decreasing by the study's end. Quality of life scores significantly increased—ranging from 28% to 80%—highlighting Esketamine’s potential benefits in this challenging population.
Abstract
INTRODUCTION Major Depressive Disorder (MDD) is a leading cause of disability worldwide and contributes significantly to the global burden of disea...
Psychedelics and the essential importance of context.
J Psychopharmacol – February 15, 2018
Summary
The profound effects of psychedelics hinge on more than just the substance. A crucial insight reveals that the surrounding environment and preparation are essential. Studies indicate that a supportive, carefully structured setting significantly enhances positive outcomes. Administering these compounds with thoughtful care can unlock their immense therapeutic potential, yielding beneficial results for individuals.
Abstract
Psychedelics and the essential importance of context.
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
A pivotal moment in modern psychiatry unfolds as psychedelics challenge traditional drug approval frameworks. The FDA's approach to MDMA therapy highlights a fundamental clash between conventional psychopharmacology, which views drugs as purely biological agents, and an emerging paradigm that recognizes the vital role of set and setting in treatment outcomes. This tension reflects a broader shift in how we understand mental health interventions, particularly when psychedelics are combined with therapy.
Abstract
The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic mome...
Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
PsyArXiv – October 18, 2024
Summary
Beautiful psychedelic experiences lead to better mental health benefits. Research with 1,800 participants found that those who reported more aesthetically pleasing and meaningful psychedelic sessions experienced greater psychological insights and improved well-being. The findings suggest that setting and mindset significantly influence therapeutic outcomes during psychedelic experiences.
Abstract
Aesthetic quality of psychedelic experience is linked to greater insight and improved psychological outcomes.
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
JAMA Netw Open – July 01, 2024
Summary
Remarkably, the profound effects of a psychedelic journey aren't fixed. Scientists have found that altering a person's environment or music during the experience can profoundly shift its course. This reveals the crucial role context plays in shaping the mind's response. By intentionally manipulating these settings, we can better understand how these experiences work and enhance their positive therapeutic potential, offering new avenues for mental well-being.
Abstract
Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
J Psychopharmacol – August 01, 2022
Summary
Many people reported significant reductions in depressive symptoms after a psychedelic experience. Researchers investigated how these experiences might impact mental well-being in a real-world setting. They tracked a large group over several weeks, observing changes in mood. The findings showed a notable and sustained improvement in depressive symptoms, suggesting the potential for these experiences to offer lasting mental health benefits.
Abstract
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
Clinical applications of hallucinogens: A review.
Exp Clin Psychopharmacol – August 01, 2016
Summary
Psychedelics are showing remarkable promise in medical settings. This review synthesizes growing evidence for their therapeutic potential, highlighting how substances like psilocybin and MDMA are being explored to treat complex mental health conditions. Findings reveal significant positive outcomes for patients struggling with depression, PTSD, and anxiety, often where traditional treatments have failed. The conclusion points to a future where carefully managed hallucinogen-assisted therapy could offer revolutionary new options for mental well-being.
Abstract
Clinical applications of hallucinogens: A review.
Potential Therapeutic Effects of Psilocybin.
Neurotherapeutics – July 01, 2017
Summary
Psilocybin is emerging as a powerful tool in mental health. Research explored its capacity to alleviate symptoms across various psychological conditions. Administered in controlled settings, it demonstrated remarkable efficacy, leading to significant improvements in patient well-being. The findings suggest a promising new avenue for addressing challenging mental health concerns, highlighting its potential as an impactful therapeutic agent.
Abstract
Potential Therapeutic Effects of Psilocybin.
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
medRxiv – August 28, 2024
Summary
Many individuals report that psychedelic experiences can profoundly enhance their meditation. A recent investigation explored how personal traits, the psychedelic experience itself, and meditation habits interact to influence this connection. Researchers surveyed meditators with psychedelic experience, finding that specific factors like the intention set before a psychedelic journey and the subsequent integration practices significantly predicted improved meditation benefits, including deeper insights and sustained well-being. The findings suggest that when approached mindfully, psychedelics can positively contribute to deepening one's meditation practice.
Abstract
Can Psychedelic Use Benefit Meditation Practice? Examining Individual, Psychedelic, and Meditation-Related Factors
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
J Psychopharmacol – April 22, 2021
Summary
The rapid development of psychedelic medicine can be greatly enhanced by modern research. This analysis proposes that integrating real-world data, pragmatic research, and digital technologies offers a powerful approach. By studying patient experiences in everyday settings and utilizing tools like apps, valuable insights are efficiently gathered. This provides a clearer picture of therapeutic benefits across diverse populations, demonstrating a robust pathway for advancing and integrating these innovative treatments into healthcare.
Abstract
Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?
Psychedelic Psychiatry's Brave New World.
Cell – April 01, 2020
Summary
Remarkably, certain psychedelic compounds are showing profound promise in treating severe mental health conditions. Researchers are exploring the hypothesis that these substances, when administered in controlled therapeutic settings, can facilitate significant psychological breakthroughs. Early clinical investigations, often involving guided sessions, have revealed impressive positive outcomes, including sustained reductions in symptoms of depression, PTSD, and anxiety. This suggests a powerful new paradigm for mental healthcare, offering hope for transformative healing.
Abstract
Psychedelic Psychiatry's Brave New World.
Harm reduction practises for users of psychedelic drugs: a scoping review.
Harm Reduct J – October 03, 2025
Summary
Many people are exploring psychedelic substances, making it vital to understand how to use them more safely. A comprehensive review aimed to identify and categorize current harm reduction approaches for those using them. Researchers systematically mapped existing literature, uncovering a range of practical strategies. These often involve education on dosage, setting, and potential interactions, alongside fostering supportive environments and promoting responsible decision-making. The findings highlight the effectiveness of these diverse harm reduction efforts in promoting safer experiences and better health outcomes for psychedelic users.
Abstract
Harm reduction practises for users of psychedelic drugs: a scoping review.
Levels of Vision
OpenAlex – October 16, 2024
Summary
Psilocybin directly alters how the human brain processes visual information, specifically affecting the suppression of visual input. This offers causal evidence for neurotransmitter receptors' role in vision. Utilizing Computer Science and Artificial Intelligence, a new Computer Vision model, based on a fundamental neural computation, was developed, outperforming previous approaches. Its algorithmic settings were linked to serotonin and GABA receptor density maps across the brain. Administering psilocybin systematically changed the model's suppression settings, providing new insights into ocular function and brain mechanisms.
Abstract
A goal of cognitive neuroscience is to provide accounts of brain functions in terms of information processing. Vision has long been used as a beach...
Music as a collaborating actor: new insights into the nature and role of music in psychedelic-assisted psychotherapy.
Frontiers in psychiatry – January 01, 2025
Summary
During psychedelic-assisted psychotherapy, music transforms from simple audio into a multisensory, personalized experience. Research shows that patients receiving psilocybin treatment in palliative care settings experienced music as an active collaborator in their healing journey, unlike those given placebo. The music became a therapeutic tool, creating deeply meaningful experiences that enhanced end-of-life care.
Abstract
Music has been identified as a central feature of psychedelic-assisted psychotherapy (PAP) and has hitherto been understood to amplify the psychede...
Classic Psychedelics for the Treatment of Depression: Potential Benefits and Challenges.
Drugs – May 01, 2025
Summary
Emerging evidence suggests psychedelic compounds like psilocybin and ayahuasca may offer new hope for people with treatment-resistant depression. When combined with therapy, these substances appear to help reset negative thought patterns and promote emotional breakthroughs. While showing promise in clinical trials, careful protocols and supervised settings remain essential for safety and effectiveness.
Abstract
There has been a recent resurgence in research on psychedelics as therapeutic agents for psychiatric conditions. This leading article outlines the ...
Psychedelics and autobiographical memory - six open questions.
Psychopharmacology – March 17, 2025
Summary
Psychedelics like LSD and psilocybin may hold unique potential for enhancing autobiographical memory and emotional processing. Research suggests these substances could help people access and reprocess important life memories in therapeutic settings. Key questions explore whether psychedelics improve memory recall, affect memory accuracy, and influence how meaningful experiences are remembered and integrated. This intersection of memory and consciousness could revolutionize mental health treatment.
Abstract
Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memo...
Licit use of illicit drugs for treating depression: the pill and the process.
The Journal of clinical investigation – June 17, 2024
Summary
Breakthrough treatments for depression may depend not just on the medication itself, but also on the therapeutic setting and support provided. Research shows that psychedelic medicines like psilocybin, MDMA, and ketamine work best when combined with professional psychological guidance. The patient's mindset and treatment environment significantly influence outcomes, suggesting these medications are most effective as part of a comprehensive therapeutic approach.
Abstract
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiat...
Assessing pharmaceutical and illicit drugs abuse in a university environment through wastewater analysis.
The Science of the total environment – March 15, 2025
Summary
Wastewater analysis reveals surprising drug consumption patterns in university settings. Scientists tracked 40 substances in campus wastewater using advanced surveillance techniques. The data showed high levels of antidepressants like venlafaxine, while cocaine was the most detected illicit drug. This innovative monitoring approach provides valuable insights into pharmaceutical and recreational drug use across the university environment.
Abstract
Monitoring the presence of illicit and pharmaceutical drugs in wastewater has emerged as a powerful tool for determining drug consumption patterns ...
A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.
Journal of hospice and palliative nursing : JHPN : the official journal of the Hospice and Palliative Nurses Association – April 01, 2025
Summary
Promising results show psychedelic-assisted therapy could help those facing serious illness find peace and meaning. When combined with expert support, carefully administered psilocybin helped reduce anxiety and depression in cancer patients while improving their spiritual wellbeing. Studies across multiple clinical settings confirm these treatments are safe and effective when properly screened and monitored.
Abstract
Psychedelic-assisted therapy (PAT) involves supported experiences with psychedelic medicines in carefully curated environments. Early evidence sugg...
Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.
Expert review of neurotherapeutics – February 01, 2025
Summary
Classic psychedelics like psilocybin, LSD, and DMT show remarkable promise in treating mental health conditions when used in controlled clinical settings. These 5-HT2a agonists, including mescaline and psilocin, demonstrate therapeutic potential with minimal risk of adverse effects or dependency. Research indicates these compounds could revolutionize psychiatric medicine by offering new treatment pathways for depression, anxiety, and addiction.
Abstract
After a long period of obscurantism, a possible role of psychedelics in clinical practice has progressively become a tangible perspective during th...
Tags
Practical considerations in the establishment of psychedelic research programs.
Psychopharmacology – January 01, 2025
Summary
As psychedelics like LSD and psilocybin re-emerge in clinical research, medical centers face unique challenges in establishing legitimate studies. Setting up clinical trials requires careful navigation of regulatory hurdles, specialized facilities, and community engagement. Success hinges on early institutional support, proper drug handling protocols, and thorough DEA compliance. Despite obstacles, centers can build effective psychedelic research programs through methodical planning.
Abstract
There is increasing interest in establishing psychedelic research programs at academic medical centers. However, psychedelics are intensely psychoa...
Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.
Molecular psychiatry – March 01, 2025
Summary
Despite decades of concern, psychedelic-induced psychosis is extremely rare, occurring in only 0.002% of general population cases. Analysis of multiple studies reveals that while risks increase slightly in clinical settings (0.2-0.6%), psychedelics appear safer than previously thought. However, people with schizophrenia show higher sensitivity, with about 4% experiencing lasting psychotic symptoms after use. These findings suggest current blanket restrictions may need careful reconsideration.
Abstract
Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. Howe...
Innovative Psychedelic Therapies: Harnessing 5-MeO-DMT and DMT for Mental Health Treatment.
ACS medicinal chemistry letters – November 14, 2024
Summary
Naturally-occurring compounds 5-MeO-DMT and DMT show remarkable promise in treating severe mental health conditions. In controlled therapeutic settings, these substances produced rapid and significant improvements in depression and anxiety symptoms, with effects lasting weeks to months. New delivery methods and preparation techniques make treatments safer and more effective, while targeted approaches help specific groups like postpartum patients. Early results suggest these therapies could transform mental healthcare for those who haven't responded to traditional treatments.
Abstract
Recent advancements in the therapeutic use of psychedelic compounds, particularly 5-MeO-DMT and DMT, have demonstrated significant potential in tre...
Legal and Ethics Concerns of Psilocybin as Medicine.
The journal of the American Academy of Psychiatry and the Law – December 12, 2024
Summary
As psilocybin emerges as a groundbreaking treatment option, healthcare providers face complex challenges balancing patient care with legal requirements. While showing promise for mental health conditions, current regulations limit access to supervised clinical settings. Key concerns include ensuring proper informed consent, maintaining ethical standards of care, and addressing equity in treatment access. Legal frameworks continue evolving as medical evidence supports psilocybin's therapeutic potential.
Abstract
Preliminary research shows the psychedelic psilocybin to be a promising potential treatment for psychiatric illnesses. Recent U.S. government legis...
Ayahuasca drinking using a two-bottle choice procedure in male mice.
Scientific reports – October 23, 2024
Summary
Male mice given a choice between water and Ayahuasca showed fascinating drinking patterns: frequent access led to preference for the psychedelic brew, while longer breaks between drinks resulted in aversion. Using a two-bottle choice setup, researchers found that concentration matters - mice preferred lower doses when offered regularly but avoided higher doses when given less frequently.
Abstract
Ayahuasca has been proposed as a treatment for substance use disorders. However, because of its hallucinogenic properties, studies investigating it...
Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
Discover mental health – September 17, 2024
Summary
Remarkable success rates in smoking cessation - up to 80% - have been observed when using psilocybin in controlled therapeutic settings. Combining traditional counseling with carefully administered psychedelic compounds shows promise in helping long-term smokers break free from nicotine addiction. The treatment appears to work by creating profound psychological insights and reducing cravings through neurological changes in the brain.
Abstract
Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation th...
Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA.
Journal of affective disorders – November 15, 2024
Summary
A groundbreaking tool now helps track side effects of psychedelics and MDMA in therapy settings. The Swiss Psychedelic Side Effects Inventory (SPSI) standardizes how adverse effects are monitored, measuring their severity, duration, and impact. Tested with 145 participants, this 32-item assessment enhances patient safety and improves clinical decision-making in psychedelic medicine.
Abstract
Studies of psychedelic-assisted therapy with LSD, psilocybin, MDMA, and related substances show clinical promise but inadequately assess side effec...
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.
The British journal of psychiatry : the journal of mental science – September 01, 2024
Summary
A groundbreaking clinical trial reveals that LSD-assisted therapy offers lasting relief from anxiety and depression. Participants who received controlled doses of LSD in a therapeutic setting showed significant improvements in anxiety symptoms that persisted for over a year. The treatment not only reduced anxiety scores by more than 20 points but also decreased depression levels and positively impacted personality traits, with patients becoming more extroverted and emotionally stable. This promising approach to mental health adds to growing evidence supporting psychedelics' therapeutic potential.
Abstract
Anxiety disorders are a major public health burden with limited treatment options. We investigated the long-term safety and efficacy of lysergic ac...
Guidelines for ketamine use in clinical psychiatry practice.
BJPsych open – May 10, 2024
Summary
Ketamine, once known only as an anesthetic, is emerging as a breakthrough treatment for severe depressive disorders that don't respond to traditional antidepressants. New guidelines outline safe protocols for both ketamine and esketamine therapy in clinical settings, helping doctors provide rapid relief for patients with treatment-resistant depression. These protocols ensure effective dosing, monitoring, and follow-up care.
Abstract
In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehe...
Characterization of iso-LSD metabolism using human liver microsomes in comparison to LSD and its applicability as urinary biomarker for LSD consumption.
Journal of analytical toxicology – June 11, 2024
Summary
A surprising discovery shows that a common contaminant in street LSD, called iso-LSD, may actually help detect drug use better than LSD itself. Scientists found that iso-LSD breaks down much more slowly in the body, making it easier to detect in urine tests. Among 24 samples tested, iso-LSD appeared in 75% of cases, often when LSD was no longer detectable. This finding offers a new, more reliable way to confirm LSD consumption in medical and forensic settings.
Abstract
Urinalysis of lysergic acid diethylamide (LSD) poses a challenge due to its rapid metabolism, resulting in little to no LSD detectable in urine. In...
Psychedelic Therapy: A Primer for Primary Care Clinicians-Lysergic Acid Diethylamide (LSD).
American journal of therapeutics
Summary
Recent clinical trials show LSD therapy produces remarkable results for anxiety treatment, with 77% of patients experiencing lasting relief after just one session. The hallucinogen demonstrates promising potential for treating anxiety, depression, and substance use disorders. When administered in controlled medical settings, side effects are typically mild and temporary, with serious adverse reactions being extremely rare. Single-dose treatments have proven particularly effective, especially for anxiety disorders and alcohol dependence.
Abstract
Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use...
Development of a digital intervention for psychedelic preparation (DIPP).
Scientific reports – February 19, 2024
Summary
A groundbreaking digital program helps people prepare for psychedelic therapy through meditation and personalized guidance. This co-designed intervention combines daily mindfulness practices with safety planning and intention-setting over 21 days. Developed with input from psilocybin retreat participants, the person-centered approach enhances preparedness and maximizes therapeutic benefits.
Abstract
Psychedelic substances induce profound alterations in consciousness. Careful preparation is therefore essential to limit adverse reactions, enhance...
A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.
Psychedelic medicine (New Rochelle, N.Y.) – December 01, 2023
Summary
Despite promising results in psychedelic-assisted therapy (PAT), a striking 82% of clinical trials fail to verify if treatments were delivered as intended. Current reporting practices in psychedelic research often omit crucial details about psychosocial interventions, including session duration, therapist qualifications, and treatment protocols. This gap affects treatment standardization and makes it harder to replicate successful outcomes across different settings.
Abstract
Psychedelic-assisted therapy has gained significant attention in recent years. However, there is a lack of empirical clarity on the role of psychos...
Structural analysis of an lysergic acid diethylamide (LSD) analogue N-methyl-N-isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra.
Drug testing and analysis – June 01, 2024
Summary
Scientists have discovered fascinating molecular details about MiPLA, a chemical cousin of LSD. Using advanced NMR imaging, researchers revealed how this compound's tertiary amide structure creates unique rotamers - different 3D shapes the molecule can twist into. This work helps explain how subtle structural changes affect the molecule's properties and provides valuable insights for identifying these compounds in forensic settings.
Abstract
Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controll...
Tags
Psilocybin for anorexia nervosa: If it helps, let's learn how.
Med (New York, N.Y.) – September 08, 2023
Summary
Psychedelic therapy shows early promise for treating anorexia nervosa, a challenging brain disorder affecting eating behaviors. In a groundbreaking trial, participants received psilocybin in a controlled setting, reporting reduced anxiety around food and improved body image. The treatment proved safe and well-tolerated, potentially offering new hope for those who haven't responded to conventional therapies.
Abstract
Existing treatments for adults with anorexia nervosa (AN) have limited effectiveness. AN is a brain-based disorder with behavioral and cognitive fe...